Retirement Systems of Alabama increased its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,261,670 shares of the biopharmaceutical company’s stock after buying an additional 786 shares during the period. Pfizer comprises about 0.8% of Retirement Systems of Alabama’s portfolio, making the stock its 16th largest position. Retirement Systems of Alabama owned 0.07% of Pfizer worth $145,792,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in PFE. Orbimed Advisors LLC boosted its stake in shares of Pfizer by 46.3% in the fourth quarter. Orbimed Advisors LLC now owns 5,167,900 shares of the biopharmaceutical company’s stock worth $167,853,000 after buying an additional 1,635,700 shares during the period. Paulson & CO. Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $11,439,000. E&G Advisors LP boosted its stake in shares of Pfizer by 6.8% in the first quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock worth $2,130,000 after buying an additional 3,940 shares during the period. Prentiss Smith & Co. Inc. boosted its stake in shares of Pfizer by 1.7% in the first quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 250 shares during the period. Finally, Carroll Financial Associates Inc. boosted its stake in shares of Pfizer by 33.9% in the first quarter. Carroll Financial Associates Inc. now owns 197,820 shares of the biopharmaceutical company’s stock worth $6,767,000 after buying an additional 50,045 shares during the period. Hedge funds and other institutional investors own 69.95% of the company’s stock.
Pfizer, Inc. (NYSE PFE) opened at 33.25 on Tuesday. The stock’s 50 day moving average price is $32.80 and its 200-day moving average price is $33.17. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $37.39. The company has a market capitalization of $198.43 billion, a P/E ratio of 27.99 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.02. The company had revenue of $12.78 billion for the quarter, compared to analysts’ expectations of $13.09 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The firm’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 earnings per share. Analysts predict that Pfizer, Inc. will post $2.55 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.85%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 108.48%.
ILLEGAL ACTIVITY WARNING: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2017/07/18/retirement-systems-of-alabama-has-145-79-million-position-in-pfizer-inc-nysepfe-updated.html.
A number of equities analysts recently issued reports on the stock. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday. Jefferies Group LLC reiterated a “hold” rating and issued a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research note on Friday. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday. BidaskClub cut shares of Pfizer from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th. Finally, Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, July 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $37.78.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.